Gland Pharma Limited has appointed Xiao Le as the Chief Investment Officer (CIO) of its wholly owned subsidiary, Gland Pharma International Pte. Ltd. (Gland Singapore), effective November 9, 2026.
In his new role, Xiao Le will be responsible for exploring investment opportunities and strengthening the company's mergers and acquisitions (M&A) capabilities across the United States, China, Singapore and other markets. He will report to the CEO of Gland Singapore.
Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharmaceuticals, diagnostics and tools, and healthcare services.
Previously, he served as Chief Financial Officer at MegaRobo Technologies in Singapore, Director on the Board of CANbridge Pharmaceuticals in the US, representing WuXi, and Senior Director of M&A and Strategic Investments at WuXi AppTec. He has also held positions at Dimensions Capital, Middleton Gardiner Group, NYSE and Bank of America Merrill Lynch.
He holds a bachelor's degree in Bio-engineering from Johns Hopkins University and a master's degree in Finance from the Massachusetts Institute of Technology (MIT).